Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression
Human Psychopharmacology: Clinical and Experimental · 2026-05 · 41 (3)
DOI: 10.1002/hup.70039 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, online erschienen am 30.03.2026. Verfasst von Juan Miguel Riestra und 9 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers New Jersey Medical School, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Bupropion, Major Depressive Disorder, Depressive Disorder, Treatment-Resistant, Memantine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
Treatment‐resistant depression (TRD) remains a formidable challenge in psychiatry, with nearly one‐third of patients with major depressive disorder (MDD) failing to respond adequately to first‐line pharmacological treatments. Pathophysiology in MDD has highlighted the N‐methyl‐D‐aspartate (NMDA) glutamatergic system as a promising therapeutic target. In 2022, the US Food and Drug Administration (FDA) approved the bupropion and dextromethorphan (DXM) combination (BDC), the first oral combination that affects both the NMDA receptor and norepinephrine‐dopamine systems. DXM is an uncompetitive NMDA receptor antagonist, and in combination with bupropion, it has been shown to be a rapidly acting oral medication with clinically significant improvement in the first week of treatment. BDC, however, has many inherent limitations such as contraindications in those with eating disorders and a history of seizures. Anxiety is a common comorbidity in MDD, and bupropion has been shown to lack efficacy in treating anxiety. In addition, BDC did not improve cognition. Memantine can treat depression and cognitive impairments concurrently. Fixed‐dose combination pills can be less flexible than prescribing each drug separately, as BDC is limited to a 105 mg (bupropion)‐45 mg (DXM) combination. The projected 1‐month cost of possible combinations of memantine ($5.00) with a selective serotonin reuptake inhibitor (SSRI, $4.00), serotonin‐norepinephrine reuptake inhibitor (SNRI, $15.00), and bupropion ($18.00) are cheaper than BDC ($1119.00). Instead of BDC, we propose various alternatives such as a bupropion‐memantine combination or SSRI/SNRI and memantine for MDD/TRD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rutgers New Jersey Medical School, Newark, New Jersey, USA.
- Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
- Department of Psychiatry, All India Institute of Medical Sciences, Bhopal, India.
- Rowan-Virtua School of Osteopathic Medicine, Stratford, New Jersey, USA.
- Department of Biological Sciences, Florida Atlantic University, Boca Raton, Florida, USA.
- School of Health Sciences, Universidad del Espíritu Santo, Samborondón, Ecuador.
ORCID-Profile: Juan Miguel Riestra, Santiago J Ballaz, Stefano Barlati
Zitieren
APA
Riestra, J. M., Levin-Carrion, Y., Sutar, R., Mitchell, J., Jambulingam, P., Ballaz, S. J., Shad, M. U., Rahman, S., Barlati, S., & Koola, M. M. (2026). Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression. Human Psychopharmacology: Clinical and Experimental, 41(3). https://doi.org/10.1002/hup.70039
Vancouver
Riestra JM, Levin-Carrion Y, Sutar R, Mitchell J, Jambulingam P, Ballaz SJ, et al. Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression. Human Psychopharmacology: Clinical and Experimental. 2026;41(3). doi:10.1002/hup.70039
BibTeX
@article{Riestra2026,
author = {Riestra, Juan Miguel and Levin-Carrion, Yaxel and Sutar, Roshan and Mitchell, Jessica and Jambulingam, Pranav and Ballaz, Santiago J and Shad, Mujeeb U and Rahman, Shafiqur and Barlati, Stefano and Koola, Maju Mathew},
title = {Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression},
journal = {Human Psychopharmacology: Clinical and Experimental},
year = {2026},
volume = {41},
number = {3},
doi = {10.1002/hup.70039}
}
EUVIMED